PALETTE- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket Trial

PALETTE is a perpetual adaptive platform to efficiently study sepsis interventions within 'treatable traits' in all-ages patients enabling prompt evaluation of pandemic treatments. Treatable traits, therapeutic targets identified by phenotypes or endotypes (defined by biological mechanism or by treatment response) through validated biomarkers (measurable characteristic reflecting normal or pathogenic processes, or treatment responses), may include multi-omics, cellular, immune, metabolic, endocrine features, or intelligent algorithms. PALETTE Bayesian adaptive design enables parallel investigations of multiple interventions for sepsis, and quick inclusion of pandemic pathogens. PALETTE's new conceptual model will respond to the challenges of standard approaches, i.e. series of sepsis trials, each investigating one or two interventions, expensive, time consuming, and inappropriate in pandemic context.

Start Date01 May 2026

Sponsor / Collaborator

Assistance Publique des Hôpitaux de Paris SA

NCT07423975

/ Not yet recruitingPhase 2IIT

Advancing Reperfusion Therapy for Ischemic Stroke (ARTS): Safety and Efficacy of Anakinra for Futile Reperfusion Following Endovascular Treatment in Patients With Acute Ischemic Stroke (SAFE)

The investigators initiated a multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled trial to explore the safety and efficacy of different dose of Anakinra compared to standard medical care for patients with acute ischemic stroke who have achieved successful recanalization after endovascular thrombectomy.

Start Date01 Mar 2026

Sponsor / Collaborator

Beijing Tiantan Hospital

NCT07281027

/ Not yet recruitingPhase 3IIT

Comparing the Effects of Anakinra and Tocilizumab on Outcomes in Patients With New-Onset Refractory Status Epilepticus

The goal of this clinical trial is to find out whether two existing medications-anakinra and tocilizumab-can effectively treat a rare and life-threatening brain condition called NORSE (New-Onset Refractory Status Epilepticus). NORSE causes continuous seizures in previously healthy children and adults and does not respond to standard treatments. It often leads to long-term disability or death.
Doctors currently use anakinra and tocilizumab as second-line treatments when first-line therapies fail, but there is no clear evidence showing which drug works better or when it should be given. This study aims to answer those questions.
The study will enroll patients across 33 hospitals in the United States, Canada, Europe, and Asia.
It includes two groups:
1. Randomized Cohort Patients will be randomly assigned to receive either anakinra or tocilizumab within the first 7 days of their illness. Only patients whose doctors were already planning to use one of these medications as part of standard care will be eligible for randomization. Researchers will monitor their recovery and compare outcomes between the two treatments.
2. Observational Cohort Patients who cannot be randomized-usually because they were diagnosed too late-will still be followed to study how the timing of treatment affects recovery.
Participants will:
* Receive one of the two medications (depending on their group assignment).
* Take part in follow-up assessments over the course of one year, including medical evaluations and surveys. Some participants may be followed annually beyond one year.
* Optionally participate in a 60-minute interview to share their or their caregiver's experience with NORSE.

Start Date01 Mar 2026

Sponsor / Collaborator

Yale University

[+1]

100 Clinical Results associated with Anakinra (Amgen)

100 Translational Medicine associated with Anakinra (Amgen)

100 Patents (Medical) associated with Anakinra (Amgen)

2,485

Literatures (Medical) associated with Anakinra (Amgen)

01 Mar 2026·Lancet Regional Health-Europe

Efficacy of anakinra in reducing progression to organ dysfunction in patients with pneumonia (INSPIRE): a randomised, double-blind, placebo-controlled, phase IIa trial

Article

Author: Kakavoulis, Nikolaos ; Psarrakis, Christos ; Giamarellos-Bourboulis, Evangelos J ; Koufargyris, Panagiotis ; Kontakou-Zoniou, Olga ; Astriti, Myrto ; Tasouli, Elisavet ; Michelakis, Evangelos ; Adamis, George ; Antonakos, Nikolaos ; Skopelitis, Ilias ; Tavoulareas, Georgios ; Dakou, Konstantina ; Sympardi, Styliani

Background:

Early recognition of risk of death in pneumonia and start of precision immunotherapy to improve outcomes is an unmet need. We hypothesized that a precision strategy approach combining early recognition of interleukin (IL)-1 activation coupled with Anakinra treatment may improve pneumonia outcome.

Methods:

INSPIRE is a prospective, double-blind randomized placebo-controlled trial which recruited hospitalized adults with community-acquired or hospital-acquired pneumonia, with qSOFA (quick sequential organ failure assessment) equal to 1 and plasma presepsin (soluble CD14) more than 350 pg/ml. Patients were 1:1 randomised to standard-of-care medication plus either subcutaneous placebo or subcutaneous Anakinra 100 mg once daily for 10 days. The primary endpoint was progression into organ dysfunction defined as meeting at least one of the following two conditions; (i) at least 2-point increase of the baseline SOFA score by day 7 and/or (ii) death by day 90. This was analyzed in the intention-to-treat (ITT) population. This trial is registered with the EU Clinical Trials Register (2022-002390-28) and ClinicalTrials.gov (NCT05785442).

Findings:

Patients were enrolled between March 2023 and June 2024; 30 patients in the placebo arm and 30 patients in the Anakinra arm were the ITT population. The primary endpoint was met in 50·0% (15 patients) of placebo-treated and in 20·0% (6 patients) of Anakinra-treated patients (difference 30·0% [5·9 to 49%]; p: 0·011). 90-day mortality was 43·3% (13 patients) and 20·0% (6 patients) (difference 23·3% [0 to 43·7%]; p: 0·029). The overall incidence of serious treatment-emergent adverse events (TEAEs) in the placebo group was 50% and in the Anakinra group 33·3%. None of the serious TEAEs was judged to be related to treatment assignment. Production of TNFα and ΙFNγ by blood mononuclear cells was decreased.

Interpretation:

Presepsin-guided Anakinra treatment prevents progression of pneumonia to organ dysfunction and death. The mechanism of benefit is associated with attenuation of cytokine production.

Funding:

Hellenic Institute for the Study of Sepsis; PHC Europe BV; Swedish Orphan Biovitrum AB.

01 Mar 2026·EUROPEAN JOURNAL OF HAEMATOLOGY

Efficacy of Etoposide‐Based Therapy in Pediatric Secondary Hemophagocytic Lymphohistiocytosis

Article

Author: Acar, Sultan Okur ; Gözmen, Salih ; Al, Işık Odaman ; Karapınar, Tuğba Hilkay ; Erdem, Melek ; Tahta, Neryal ; Oymak, Yeşim

ABSTRACT:

Objectives:

Secondary hemophagocytic lymphohistiocytosis (sHLH) is a severe hyperinflammatory syndrome requiring rapid recognition and treatment. Despite the expanding availability of biologic and cytokine‐directed therapies, etoposide‐based immunochemotherapy remains the primary treatment in many pediatric centers. This study evaluated the efficacy, response kinetics, and clinical outcomes of etoposide‐based therapy in children with sHLH.

Methods:

We retrospectively analyzed 32 pediatric patients diagnosed with sHLH between 2018 and 2023 at a tertiary center. Diagnosis was based on HLH‐2004 criteria; primary HLH was excluded through genetic testing when available. All patients received dexamethasone and etoposide, with cyclosporine A initiated after Week 1. Trigger‐directed therapies included rituximab for EBV‐HLH and anakinra or tocilizumab in selected hyperinflammatory states. Laboratory dynamics (ferritin, fibrinogen, platelets, and absolute neutrophil count), clinical responses, relapse, hematopoietic stem cell transplantation (HSCT), and overall survival (OS) were assessed.

Results:

The median age was 38 months; 62.5% were male. Triggers included EBV (34%), other viral infections (19%), rheumatologic disease/MAS (16%), bacterial infection (13%), and malignancy (9%). By Week 4, ferritin decreased from 6480 to 1240 ng/mL and fibrinogen increased from 122 to 286 mg/dL ( p < 0.001). Fever resolved in 90% by Week 2, and 81% achieved complete laboratory response. During a median follow‐up of 18 months, relapse occurred in 18.8% and HSCT was required in 15.6% of patients. Overall survival was 91% at 1 year and 86% at 2 years. Adverse events were consistent with expected etoposide‐related toxicities.

Conclusion:

Etoposide‐based immunochemotherapy provided rapid disease control and favorable survival in pediatric sHLH. These findings support the continued relevance of etoposide while underscoring the need for risk‐adapted approaches integrating trigger‐directed therapy, cytokine inhibitors, and timely HSCT in selected patients.

01 Feb 2026·DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

ZNFX1 deficiency presenting as recurrent HLH triggered by CMV infection

Article

Author: Mirza, Aisha ; Goronfolah, Loie ; Khojah, Amer ; Obaid, Nora Bin ; Lohaibi, Rayan Al

Interferons (IFNs) are essential cytokines in host defense, particularly against viral pathogens. Dysregulation of IFN signaling can result in increased susceptibility to viral infections, systemic inflammation. We report a 6-month-old male who presented with hemophagocytic lymphohistiocytosis (HLH) triggered by cytomegalovirus (CMV) infection. He was admitted to the Pediatric Intensive Care Unit due to fever and respiratory distress. Laboratory findings revealed pancytopenia, elevated inflammatory markers, and laboratory markers suggestive of HLH. Whole-exome sequencing revealed a novel homozygous nonsense variant in ZNFX1 (c.1928G>A, p.Trp643X). During subsequent hospitalization, he developed CMV reactivation, gastrointestinal symptoms, neurologic deterioration, and multiorgan dysfunction. Despite intensive supportive care and immunomodulation with anakinra and corticosteroids, the patient progressed to irreversible organ failure and died from respiratory failure. This case expands the clinical and genetic spectrum of ZNFX1 deficiency and highlights the importance of considering monogenic interferonopathies in children with severe viral infections, HLH, and unexplained systemic inflammation.

News (Medical) associated with Anakinra (Amgen)

24 Feb 2026

·www.biospace.com

Kiniksa Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Portfolio Execution

– ARCALYST ® (rilonacept) Q4 2025 and full year 2025 net product revenue of $202.1 million and $677.6 million, respectively – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by the end of 2026 – – Cash balance increased by $170.4 million in 2025 to $414.1 million – – Conference call and webcast scheduled for 8:30 am ET today – LONDON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- – Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today reported fourth quarter and full year 2025 financial results and recent portfolio execution. “Kiniksa continued to drive significant advancements across its commercial and clinical portfolio in 2025. The expanding adoption of IL-1α & IL-1β inhibition with ARCALYST as the preferred second-line treatment for recurrent pericarditis helped drive 62% year-over-year ARCALYST sales growth to $677.6 million. We believe substantial opportunity remains for ARCALYST and we expect 2026 sales of between $900 and $920 million,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Within our clinical pipeline, we expanded our leadership in recurrent pericarditis with the initiation of the KPL-387 Phase 2/3 development program, which could provide an important additional treatment option for patients. We also plan to initiate a Phase 1 trial with KPL-1161, an Fc-modified monoclonal antibody IL-1 receptor antagonist by the end of this year. Importantly, Kiniksa has a robust financial pro supports these efforts and provides the ability to invest in additional value-creating opportunities.” Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap) ARCALYST net product revenue was $202.1 million and $677.6 million for the fourth quarter and full year 2025, respectively. Gross-to-net was 8.4% for the full year 2025 compared to 9.8% for the full year 2024, due to the impact of the Inflation Reduction Act throughout 2025, as well as prior period reserve adjustments in the fourth quarter of 2025. As of the end of the fourth quarter of 2025, approximately 18% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment. Since launch, more than 4,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis. Average total duration of ARCALYST therapy in recurrent pericarditis continues to grow and is approaching 3 years, in line with the median duration of disease. KPL-387 (monoclonal antibody IL-1 receptor antagonist) Kiniksa is conducting a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis and expects data from the dose-focusing portion of the trial in the second half of 2026. Kiniksa is conducting a supplemental Phase 2 Transition to KPL-387 Monotherapy Dosing & Administration Study evaluating the efficacy and safety of the dosing regimens used to transition patients from standard therapies to KPL-387 monotherapy. KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist) Kiniksa is conducting preclinical development activities with KPL-1161 with a target pro quarterly subcutaneous (SC) dosing. The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026. Financial Results Total revenue for the fourth quarter of 2025 was $202.1 million, compared to $122.5 million for the fourth quarter of 2024. Total revenue for the fourth quarter of 2025 and the fourth quarter of 2024 did not include any license and collaboration revenue. Total revenue for the full year 2025 was $677.6 million, compared to $423.2 million for the full year 2024. Total revenue for the full year 2025 did not include any license and collaboration revenue, compared to $6.2 million for the full year 2024. Total operating expenses for the fourth quarter of 2025 were $182.4 million, compared to $141.8 million for the fourth quarter of 2024. Total operating expenses for the fourth quarter of 2025 included $70.0 million in collaboration expenses, which are driven by ARCALYST collaboration profitability, compared to $48.2 million for the fourth quarter of 2024. 1 Total operating expenses for the fourth quarter of 2025 included $10.2 million in non-cash, share-based compensation expense, compared to $8.3 million for the fourth quarter of 2024. Total operating expenses for the full year 2025 were $600.3 million, compared to $468.9 million for the full year 2024. Total operating expenses for the full year 2025 included $229.5 million in collaboration expenses, which are driven by ARCALYST collaboration profitability, compared to $128.3 million for the full year 2024. 1 Total operating expenses for the full year 2025 included $37.0 million in non-cash, share-based compensation expense, compared to $30.7 million for the full year 2024. Net income for the fourth quarter of 2025 was $14.2 million, compared to a net loss of $8.9 million for the fourth quarter of 2024. Net income for the full year 2025 was $59.0 million, compared to net loss of $43.2 million for the full year 2024. As of December 31, 2025, Kiniksa had $414.1 million of cash, cash equivalents, and short-term investments and no debt, compared to $243.6 million as of December 31, 2024. Financial Guidance Kiniksa expects 2026 ARCALYST net product revenue of between $900 million and $920 million. Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. Conference Call Information Kiniksa will host a conference call and webcast at 8:30 a.m. Eastern Time on Tuesday, February 24, 2026, to discuss fourth quarter and full year 2025 financial results and to provide a corporate update. Individuals interested in participating in the call via telephone may register here . Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. To access the webcast, please visit the Investors and Media section of Kiniksa’s website. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event. About Kiniksa Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit . About ARCALYST ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved by the FDA for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older, and the maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more. The FDA granted Orphan Drug Exclusivity to ARCALYST upon its approval for recurrent pericarditis in 2021. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021. IMPORTANT SAFETY INFORMATION ABOUT ARCALYST ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection). While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel® (etanercept), Humira® (adalimumab), or Remicade® (infliximab), as this may increase your risk of getting a serious infection. Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST. Medicines that affect the immune system may increase the risk of getting cancer. Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction. Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides. Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose. For more information about ARCALYST, talk to your doctor and see the Product Information . About KPL-387 KPL-387 is an independently developed, investigational, fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling of the cytokines IL-1α and IL-1β. Kiniksa believes KPL-387 could expand the treatment options for recurrent pericarditis patients by potentially enabling dosing with a single monthly SC self-injection in a liquid formulation. In October 2025, the FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis. About KPL-1161 KPL-1161 is an independently developed, investigational, Fc-modified IgG2 monoclonal antibody that binds IL-1R1, inhibiting the signaling of the cytokines IL-1α and IL-1β, with a target pro quarterly SC dosing. Kiniksa is currently engaging in preclinical development activities for KPL-1161. Forward-Looking Statements This press release contains forward-looking statements. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST 2026 net product revenue will be between $900 million and $920 million; our belief that data from the dose-focusing portion of our Phase 2 clinical trial of KPL-387 in recurrent pericarditis will be available in the second half of 2026; our plan to initiate a Phase 1 first-in-human clinical trial of KPL-1161 by the end of 2026; our belief that KPL-387 could provide an important additional treatment option for recurrent pericarditis patients; our belief that our robust financial pro provide the ability to invest in additional value creation; our target pro quarterly subcutaneous dosing for KPL-1161; our beliefs about the mechanisms of our assets and potential impact of their approach; statements regarding our belief about the future of our commercial opportunities; and our belief that our portfolio of assets offers the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; business development activities and their impact on our financial performance and strategy; changes in our operating plan, business development strategy or funding requirements; existing or new competition; current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; and the impact of global economic policy, including any uncertainty in national and international markets. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. ARCALYST® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second Counts! ® Kiniksa Investor & Media Contact Jonathan Kirshenbaum (781) 829-3949 jkirshenbaum@kiniksa.com KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC SELECTED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (In thousands) (Unaudited) Three Months Ended Years Ended December 31, December 31, 2025 2024 2025 2024 Revenue: Product revenue, net $ 202,127 $ 122,536 $ 677,564 $ 417,029 License and collaboration revenue — — — 6,210 Total revenue 202,127 122,536 677,564 423,239 Costs and operating expenses: Cost of goods sold 20,945 17,896 77,673 60,910 Collaboration expenses 70,030 48,189 229,545 128,311 Research and development 34,609 35,215 96,853 111,623 Selling, general and administrative 56,775 40,535 196,272 168,011 Total operating expenses 182,359 141,835 600,343 468,855 Income (loss) from operations 19,768 (19,299 ) 77,221 (45,616 ) Other income, net 3,501 2,320 11,647 9,464 Income (loss) before income taxes 23,269 (16,979 ) 88,868 (36,152 ) Benefit (provision) for income taxes (9,070 ) 8,091 (29,863 ) (7,041 ) Net income (loss) $ 14,199 $ (8,888 ) $ 59,005 $ (43,193 ) Net income (loss) per share attributable to ordinary shareholders—basic $ 0.19 $ (0.12 ) $ 0.80 $ (0.60 ) Net income (loss) per share attributable to ordinary shareholders—diluted $ 0.17 $ (0.12 ) $ 0.75 $ (0.60 ) Weighted average ordinary shares outstanding—basic 75,967,217 72,319,129 74,200,924 71,424,159 Weighted average ordinary shares outstanding—diluted 81,566,313 72,319,129 78,979,030 71,424,159 KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC SELECTED CONSOLIDATED BALANCE SHEET DATA (In thousands) (Unaudited) As of December 31, December 31, 2025 2024 Cash, cash equivalents, and short-term investments $ 414,074 $ 243,627 Working capital 387,993 231,178 Total assets 763,633 580,553 Accumulated deficit (462,138 ) (521,143 ) Total shareholders' equity 567,606 438,436 1 Q4 2024 and 2024 collaboration expenses included a $10.0 million charge for Regeneron’s share of a $20.0 million milestone received from Huadong Medicine for approval of ARCALYST in China.

Drug ApprovalPhase 1Orphan DrugFinancial StatementPhase 2

12 Jan 2026

·www.biospace.com

Kiniksa Pharmaceuticals Provides Corporate Update

– ARCALYST ® (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth – – ARCALYST 2026 net product revenue expected to be $900 - $920 million – – KPL-387 Phase 2 recurrent pericarditis data expected in 2H 2026 – – KPL-1161 Phase 1 trial planned to initiate by year end – – Cash balance increased by $170.4 million in 2025 to $414.1 million (unaudited) – LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications, today provided a corporate update. “IL-1α & IL-1β inhibition with ARCALYST is increasingly becoming the preferred second line treatment for patients with recurrent pericarditis. As of the end of 2025, approximately 18% of the multiple recurrence population was actively on ARCALYST therapy. In addition to driving further uptake in this group, we are well-positioned to expand our reach in the broader population of first recurrence patients,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “We are also advancing KPL-387 in recurrent pericarditis, which we believe could expand the IL-1α & IL-1β inhibition market by potentially enabling monthly self-administration with a liquid formulation. We are enrolling and dosing patients in the Phase 2 dose-focusing portion of the Phase 2/3 trial, with data expected in the second half of 2026. In addition, we plan to commence a Phase 1 first-in-human trial with KPL-1161, an Fc-modified monoclonal antibody IL-1 receptor antagonist, by the end of this year. Our strong financial position supports these efforts as well as provides the ability to pursue additional value-creating opportunities.” Portfolio Execution ARCALYST (IL-1α and IL-1β cytokine trap) ARCALYST net product revenue was $677.5 million (unaudited) for the full year 2025, compared to $417.0 million for the full year 2024, representing approximately 62% year-over-year growth. Gross-to-net was 8.4% (unaudited) for the full year 2025 compared to 9.8% for the full year 2024, due to the impact of the Inflation Reduction Act throughout 2025, as well as prior period reserve adjustments in the fourth quarter of 2025. As of the end of the fourth quarter of 2025, approximately 18% of the 14,000 multiple-recurrence patients were actively on ARCALYST treatment. Since launch, more than 4,150 prescribers have written ARCALYST prescriptions for recurrent pericarditis. Average total duration of ARCALYST therapy in recurrent pericarditis continues to grow and is approaching 3 years, in line with the median duration of disease. Kiniksa expects 2026 ARCALYST net product revenue of between $900 million and $920 million. KPL-387 (monoclonal antibody IL-1 receptor antagonist) Kiniksa is conducting a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis and expects data from the dose-focusing portion in the second half of 2026. Kiniksa is conducting a supplemental Phase 2 Transition to KPL-387 Monotherapy Dosing & Administration Study evaluating the efficacy and safety of the dosing regimens used to transition patients from standard therapies to KPL-387 monotherapy. KPL-1161 (Fc-modified monoclonal antibody IL-1 receptor antagonist) Kiniksa is conducting preclinical development activities with KPL-1161 with a target pro quarterly subcutaneous (SC) dosing. The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026. Corporate Update As of December 31, 2025, Kiniksa had $414.1 million of cash, cash equivalents, and short-term investments and no debt (unaudited). Kiniksa expects its current operating plan to remain cash flow positive on an annual basis. 44 th Annual J.P. Morgan Healthcare Conference Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa and Ross Moat, Chief Corporate and Commercial Officer, will provide a corporate presentation at the 44 th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time). A live webcast of Kiniksa’s presentation will be accessible through the Investors & Media section of the company’s website at . A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours after the event. About Kiniksa Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit . About ARCALYST ARCALYST is a weekly, subcutaneously injected recombinant dimeric fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling. ARCALYST was discovered by Regeneron Pharmaceuticals, Inc. (Regeneron) and is approved by the U.S. Food and Drug Administration (FDA) for the treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older. ARCALYST is also approved by the FDA for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older, and the maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more. The FDA granted Orphan Drug Exclusivity to ARCALYST upon its approval for recurrent pericarditis in 2021. The European Commission granted Orphan Drug Designation to ARCALYST for the treatment of idiopathic pericarditis in 2021. IMPORTANT SAFETY INFORMATION ABOUT ARCALYST ARCALYST may affect your immune system and can lower the ability of your immune system to fight infections. Serious infections, including life-threatening infections and death, have happened in patients taking ARCALYST. If you have any signs of an infection, call your doctor right away. Treatment with ARCALYST should be stopped if you get a serious infection. You should not begin treatment with ARCALYST if you have an infection or have infections that keep coming back (chronic infection). While taking ARCALYST, do not take other medicines that block interleukin-1, such as Kineret ® (anakinra), or medicines that block tumor necrosis factor, such as Enbrel ® (etanercept), Humira ® (adalimumab), or Remicade ® (infliximab), as this may increase your risk of getting a serious infection. Talk with your doctor about your vaccine history. Ask your doctor whether you should receive any vaccines before you begin treatment with ARCALYST. Medicines that affect the immune system may increase the risk of getting cancer. Stop taking ARCALYST and call your doctor or get emergency care right away if you have any symptoms of an allergic reaction. Your doctor will do blood tests to check for changes in your blood cholesterol and triglycerides. Common side effects include injection-site reactions (which may include pain, redness, swelling, itching, bruising, lumps, inflammation, skin rash, blisters, warmth, and bleeding at the injection site), upper respiratory tract infections, joint and muscle aches, rash, ear infection, sore throat, and runny nose. For more information about ARCALYST, talk to your doctor and see the Product Information . About KPL-387 KPL-387 is an independently developed, investigational, fully human immunoglobulin G2 (IgG2) monoclonal antibody that binds human interleukin-1 receptor 1 (IL-1R1), inhibiting the signaling of the cytokines IL-1α and IL-1β. Kiniksa believes KPL-387 could expand the treatment options for recurrent pericarditis patients by potentially enabling dosing with a single monthly SC self-injection in a liquid formulation. In October 2025, the FDA granted Orphan Drug Designation to KPL-387 for the treatment of pericarditis. About KPL-1161 KPL-1161 is an independently developed, investigational, Fc-modified IgG2 monoclonal antibody that binds IL-1R1, inhibiting the signaling of the cytokines IL-1α and IL-1β, with a target pro quarterly SC dosing. Kiniksa is currently engaging in preclinical development activities for KPL-1161. Forward-Looking Statements This press release contains forward-looking statements. In some cases, you can identify forward looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these identifying words. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation, statements regarding: our expectation that ARCALYST 2026 net product revenue will be between $900 million and $920 million; our belief that data from the dose-focusing portion of our Phase 2 clinical trial of KPL-387 in recurrent pericarditis will be available in the second half of 2026; our plan to initiate a Phase 1 first-in-human clinical trial of KPL-1161 by the end of 2026; our belief that we are well-positioned to expand ARCALYST’s reach into the broader population of first recurrence patients; our belief that KPL-387 could expand the IL-1α & IL-1β inhibition market by potentially enabling monthly subcutaneous self-administration with a liquid formulation; our target pro quarterly subcutaneous dosing for KPL-1161; our beliefs about the mechanisms of our assets and potential impact of their approach; statements regarding our belief about the future of our commercial opportunities; and our belief that our portfolio of assets offers the potential for differentiation. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including without limitation, the following: delays or difficulty in enrollment of patients in, and activation or continuation of sites for, our clinical trials; delays or difficulty in completing our clinical trials as originally designed; potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials; our inability to replicate results from our earlier clinical trials or studies; impact of additional data from us or other companies, including the potential for our data to produce negative, inconclusive or commercially uncompetitive results; potential undesirable side effects caused by our products and product candidates; our inability to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities; potential for applicable regulatory authorities to not accept our filings, delay or deny approval of any of our product candidates or require additional data or trials to support approval; our reliance on third parties as the sole source of supply of the drug substance and drug product used in our products and product candidates; raw material, important ancillary product and drug substance and/or drug product shortages; our reliance on third parties to conduct research, clinical trials, and/or certain regulatory activities for our product candidates; complications in coordinating requirements, regulations and guidelines of regulatory authorities across jurisdictions for our clinical trials; business development activities and their impact on our financial performance and strategy; changes in our operating plan, business development strategy or funding requirements; existing or new competition; current and future healthcare reforms, including those affecting the delivery of or payment for healthcare products and services; and the impact of global economic policy, including any uncertainty in national and international markets. These and other important factors discussed in our filings with the U.S. Securities and Exchange Commission, including under the caption “Risk Factors” contained therein, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. Except as required by law, we disclaim any intention or obligation to update or revise any forward-looking statements. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. ARCALYST ® is a registered trademark of Regeneron Pharmaceuticals, Inc. Every Second Counts! ® Kiniksa Investor & Media Contact Jonathan Kirshenbaum (781) 829-3949 jkirshenbaum@kiniksa.com

Phase 1Drug ApprovalOrphan DrugPhase 2Immunotherapy

07 Jan 2026

·www.sobi.com

Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data

Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival. Based on the observed data from this research collaboration with the Hellenic Institute for the Study of Sepsis (HISS), Sobi and HISS will advance emapalumab in IDS and discuss the next clinical development steps with regulatory authorities. An update on next steps will be provided in due course and data from the EMBRACE study will be published at an upcoming medical conference. About sepsis and IFNγ-driven sepsis (IDS) Sepsis is a serious condition in response to an infection that can lead to organ failure and is a leading global cause of mortality. A recent large study, published in eBioMedicine in 20241 describes different sepsis endotypes, suggesting varying endotypes require differentiated treatment strategies. Approximately 20% of the patients studied are of the newly described IFNγ-driven sepsis (IDS) endotype. IDS is marked by elevated levels of CXCL9 and detection of IFNγ and poor clinical outcomes, with a 28-day mortality rate ranging from 40 to 43%. About the EMBRACE study The EMBRACE study (NCT06694701) was a Phase 2a, double-blind, randomized controlled trial was conducted at 24 sites in Greece. The study was sponsored by the Hellenic Institute for the Study of Sepsis (HISS) as part of a research collaboration with Sobi. The trial investigated whether Gamifant, an anti-IFNγ antibody, can improve clinical outcomes in patients with the interferon gamma-driven sepsis (IDS) endotype and absence of sepsis-induced immunoparalysis. IDS is characterized by elevated levels of CXCL9 and detectable IFNγ and is associated with poor patient outcomes. By targeting this inflammation pathway, the EMBRACE trial aims to reduce mortality, improve organ function, and accelerate recovery. The trial design includes three arms (a total of 75 patients enrolled), two groups receiving Gamifant, (low and high doses) alongside standard-of-care treatment, and one group receiving placebo alongside standard-of-care treatment. The primary endpoint is a ≥1.4-point decrease in the Sequential Organ Failure Assessment (SOFA) score from baseline to the end of treatment (28 days). Secondary endpoints include 28-day mortality, safety, pharmacokinetics, and changes in key inflammatory biomarkers such as CRP, IL-6, ferritin, IFNγ, and CXCL9. About GamifantGamifant® (emapalumab) is an anti-interferon gamma (IFNγ) monoclonal antibody that binds to and neutralises IFNγ. When IFNγ is secreted in an uncontrolled manner, hyperinflammation occurs within the body. Gamifant is indicated for administration through intravenous infusion over one hour twice per week until haematopoietic stem cell transplantation (HSCT). In the USA, Gamifant is indicated for the treatment of adult and paediatric (newborn and older) patients with primary haemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. Gamifant is also approved in the US for the treatment of adult and pediatric (newborn and older) patients with hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) in known or suspected Still’s disease with an inadequate response or intolerance to glucocorticoids, or with recurrent MAS. Primary HLH is a rare syndrome of hyperinflammation that usually occurs within the first year of life and can rapidly become fatal unless diagnosed and treated. About HISS The Hellenic Institute for the Study of Sepsis (HISS) is a non-profit, academic institute which fosters the activities of young researchers in the fields of systemic inflammation and sepsis. Since 2010, HISS has published 125 peer-reviewed publications including the publication of guidelines for sepsis in Greece, led the organization of 15 conferences, and of 35 clinical studies. HISS focuses on precision immunotherapy and is the Sponsor of the major randomized controlled trials SAVE-MORE and ImmunoSep. The data from these studies have been published in journals such as Nature Medicine and JAMA. 2,3. For more information, please visit https://sepsis.gr . Sobi Sobi® is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 6 PM CET on 7 January 2026. Reference 1: Interferon-gamma-driven elevation of CXCL9: a new sepsis endotype independently associated with mortality. Giamarellos-Bourboulis, Evangelos J. et al. eBioMedicine, Volume 109, 105414 2: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Kyriazopoulou, Evdoxia et al. Nature Medicine 2021 Oct;27(10):1752-1760. 3: Precision Immunotherapy to Improve Sepsis Outcomes. The ImmunoSep Randomized Clinical Trial. Giamarellos-Bourboulis EJ, et al. JAMA, DOI: 10.1001/jama.2025.24175. We are a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Our therapies are concentrated within the areas of Haematology, Immunology and Specialty Care. We contribute to societies by improving access to treatment of rare diseases. Find out more about our business and financial performance. Here we present our most recent press releases, stories, news articles, and images. Every day, we work actively to find better ways to understand and meet patient needs.

Clinical ResultPhase 2Phase 3ImmunotherapyDrug Approval

100 Deals associated with Anakinra (Amgen)

External Link

KEGG	Wiki	ATC	Drug Bank
D02934	Anakinra (Amgen)	L04AC03	DB00026

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Deficiency of Interleukin-1 Receptor Antagonist	United States	Swedish Orphan Biovitrum AB	18 Dec 2020
COVID-19	European Union	Swedish Orphan Biovitrum AB	08 Mar 2002
COVID-19	Iceland	Swedish Orphan Biovitrum AB	08 Mar 2002
COVID-19	Liechtenstein	Swedish Orphan Biovitrum AB	08 Mar 2002
COVID-19	Norway	Swedish Orphan Biovitrum AB	08 Mar 2002
Cryopyrin-Associated Periodic Syndromes	European Union	Swedish Orphan Biovitrum AB	08 Mar 2002
Cryopyrin-Associated Periodic Syndromes	Iceland	Swedish Orphan Biovitrum AB	08 Mar 2002
Cryopyrin-Associated Periodic Syndromes	Liechtenstein	Swedish Orphan Biovitrum AB	08 Mar 2002
Cryopyrin-Associated Periodic Syndromes	Norway	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial cold urticaria	European Union	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial cold urticaria	Iceland	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial cold urticaria	Liechtenstein	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial cold urticaria	Norway	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial Mediterranean Fever	European Union	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial Mediterranean Fever	Iceland	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial Mediterranean Fever	Liechtenstein	Swedish Orphan Biovitrum AB	08 Mar 2002
Familial Mediterranean Fever	Norway	Swedish Orphan Biovitrum AB	08 Mar 2002
Muckle-Wells Syndrome	European Union	Swedish Orphan Biovitrum AB	08 Mar 2002
Muckle-Wells Syndrome	Iceland	Swedish Orphan Biovitrum AB	08 Mar 2002
Muckle-Wells Syndrome	Liechtenstein	Swedish Orphan Biovitrum AB	08 Mar 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Mucocutaneous Lymph Node Syndrome	Phase 3	France	Swedish Orphan Biovitrum AB	20 Oct 2023
Respiratory Failure	Phase 3	Italy	Swedish Orphan Biovitrum AB	28 Jan 2021
Inflammation	Phase 3	United States	Swedish Orphan Biovitrum AB	02 Apr 2020
Inflammation	Phase 3	Italy	Swedish Orphan Biovitrum AB	02 Apr 2020
Respiratory Distress Syndrome	Phase 3	United States	Swedish Orphan Biovitrum AB	02 Apr 2020
Respiratory Distress Syndrome	Phase 3	Italy	Swedish Orphan Biovitrum AB	02 Apr 2020
Idiopathic Recurrent Pericarditis	Phase 3	Italy	Swedish Orphan Biovitrum Ltd.	09 Jul 2013
Cystitis, Interstitial	Phase 2	Sweden	SelectImmune Pharma AB	22 Apr 2022
Brain metastases	Phase 2	Netherlands	Swedish Orphan Biovitrum AB	16 Mar 2022
Hemorrhagic stroke	Phase 2	Netherlands	Swedish Orphan Biovitrum AB	16 Mar 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05785442 (INSPIRE, Pubmed \| Lancet Reg Health Eur)	Phase 2	Pneumonia	60	Anakinra 100 mg	mljbafsjyq(pdjgmwlguc) = hdudwnlcti fpvibrdosd (ytyynmdfpy ) View more	Positive	01 Mar 2026
NCT05785442 (INSPIRE, Pubmed \| Lancet Reg Health Eur)	Phase 2	Pneumonia	60	Placebo	wdyqwhrimt(wjxtutbvqs) = cmgiwiewrc ohazmelwup (yrwwcypzbk ) View more	Positive	01 Mar 2026
NCT04747847 (CTgov)	Early Phase 1	Coronary Occlusion \| Mucocutaneous Lymph Node Syndrome	5	Atorvastatin+anakinra	iypwnwtehl = alfeeagogh oouziskhup (nfxtrgzcgn, qmjuzxhdbm - uesozsuaja) View more	-	25 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Steroid Refractory Graft Versus Host Disease	28	Anakinra	dxndbdfxbl(bnzsaouqyi) = knsreumaog tldpzybzzw (tkumwieeaw ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Hematologic Neoplasms	16	Anakinra and Corticosteroids	eotsghmpms(wolswdcayi) = dfiwtcliai fqiufigkww (zvjeumveiv ) View more	Negative	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	CD19-positive B-cell acute lymphoblastic leukemia \| Non-Hodgkin Lymphoma	39	Anakinra prophylaxisTisagenlecleucelaxis + Anakinra prophylaxisTisagenlecleucel	uupydpyjjh(jvbzecthbt) = aryonuwvwm usouaqqxie (vumqlcxxwh ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable		39	Anakinra prophylaxisBrexucabtagene autoleucel + Anakinra prophylaxisBrexucabtagene autoleucel	uupydpyjjh(nydqsettxz) = rcznkfhbrt ahtzrawnvp (qpstjdjxsj ) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Neurotoxicity Syndromes	101	Anakinra	mtwksdnfhl(qibfoofkpo) = sgdjerjpfh hfrugybnxm (mmyzbezgmo, 78 - 92) View more	Positive	04 Feb 2026
Tandem Meetings ASTCT and CIBMTR2026	Not Applicable	Neurotoxicity Syndromes	42	Anakinra (Large B-cell lymphoma + ICANS)	zqhjncomva(buiwkqlxez) = vlpknulzgw uedidopvyu (hcbdnxpbjv ) View more	Positive	04 Feb 2026
NCT02929251 (Pubmed \| Am J Ophthalmol)	Phase 2	Non-infectious posterior uveitis	112	adalimumab	mmuqwrcnoi(orjjshsxul) = wjfkregiqp bwyujtthvg (xuqokdgxuk ) View more	Positive	01 Feb 2026
NCT02929251 (Pubmed \| Am J Ophthalmol)	Phase 2	Non-infectious posterior uveitis	112	Tocilizumab	mmuqwrcnoi(orjjshsxul) = rxztyoycyo bwyujtthvg (xuqokdgxuk ) View more	Positive	01 Feb 2026
ASH2025	Not Applicable	B-Cell Lymphoma	45	Anakinra 100 mg IV	xqbbjarjch(tcjnowhfft) = vyxepyhpvz ljicwaqecv (fynyjtioca ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	B-Cell Lymphoma	45	No Anakinra	xqbbjarjch(tcjnowhfft) = eriryizfbd ljicwaqecv (fynyjtioca ) View more	Positive	06 Dec 2025
ASH2025	Not Applicable	Lymphohistiocytosis, Hemophagocytic TP53 \| DNMT3A \| TET2 ... View more	91	Leukemia-directed chemotherapy	bcmsyfcxvm(kqniljdsou) = wfaymbjpnl icrjxpwmpk (wnpoipvbcp ) View more	Negative	06 Dec 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis